Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.38 |
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 2/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.31 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
| ▸ | TSPO | P30536 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.31 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.31 |
| ▸ | CACNG8 | Q8WXS5 | 1/20 | 0.31 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16045535 | 0.82 | CSNK2A1 (0.37) | ALDH1A1HPGDCSNK2A1 | |
| SCHEMBL6333464 | 0.79 | CYP1A1 (0.40) | ALDH1A1HPGDCYP1A1CYP1A2CYP1B1 | |
| SCHEMBL29893592 | 0.79 | HPGD (0.40) | ALDH1A1HPGDKDM4ETDP1TAAR1 | |
| SCHEMBL837981 | 0.79 | HPGD (0.40) | ALDH1A1HPGDKDM4ETDP1TAAR1 | |
| SCHEMBL29446718 | 0.79 | CYP1A2 (0.48) | ALDH1A1HPGDCYP1A1CYP1A2CYP1B1 | |
| SCHEMBL6299 | 0.79 | CYP1A2 (0.48) | ALDH1A1HPGDCYP1A1CYP1A2CYP1B1 | |
| SCHEMBL27701765 | 0.78 | ALDH1A1 (0.39) | ALDH1A1HPGDKDM4ETDP1TAAR1 | |
| Ammonia Solution, Strong SCHEMBL28135352 | 0.77 | CYP1A2 (0.46) | ALDH1A1HPGDCYP1A1CYP1A2CYP1B1 | |
| SCHEMBL13278320 | 0.76 | GABRA1 (0.48) | ALDH1A1HPGDCYP1A1CYP1A2CYP1B1 | |
| SCHEMBL24108195 | 0.76 | ALDH1A1 (0.38) | ALDH1A1HPGDKDM4ETDP1FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026103873-A1 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | 杭州百新生物医药科技有限公司 | 2026-05-21 | — | — | WO | disclosed |
| WO-2025262295-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | DARK BLUE THERAPEUTICS LTD (GB) | 2025-12-26 | — | — | WO | disclosed |
| EP-4667464-A1 | AZOLYLPYRIDINE PYRIDAZINONE AMIDE AS SOS1 INHIBITOR | Cyrus Therapeutics Inc. (KR) | 2025-12-24 | — | — | EP | disclosed |
| EP-4667466-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | Dark Blue Therapeutics Ltd (GB) | 2025-12-24 | — | — | EP | disclosed |
| EP-4323354-B1 | 2-((4-((S)-2-(4-CHLORO-2-FLUOROPHENYL)-2-METHYLBENZO[D][1,3]DIOXOL-4-YL)PIPERIDIN-1-YL)METHYL)-1-(((S)-OXETAN-2-YL)METHYL)-1H-IMIDAZOLE DERIVATIVES AS ACTIVATORS OF THE GLP1 RECEPTOR FOR THE TREATMENT OF OBESITY | NOVARTIS AG (CH) | 2025-12-17 | — | — | EP | disclosed |
| EP-4081521-B1 | SUBSTITUTED TRICYCLIC COMPOUNDS | LUPIN LTD (IN) | 2025-12-10 | — | — | EP | disclosed |
| EP-4648853-A1 | TARGETED DEGRADATION OF VAV1 | Monte Rosa Therapeutics AG (CH) | 2025-11-19 | — | — | EP | disclosed |
| US-20250214977-A1 | STAT6 INHIBITORS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-07-03 | — | — | US | disclosed |
| US-20250205219-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS AG (CH) | 2025-06-26 | — | — | US | disclosed |
| US-20250197420-A1 | MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2025-06-19 | — | — | US | disclosed |
| WO-2013134562-A1 | TRIAZOLONE COMPOUNDS AND USES THEREOF | INCEPTION 2, INC. (US) | 2013-09-12 | — | — | WO | disclosed |
| CN-103201262-A | Autotaxin inhibitors and uses thereof | AMIRA PHARMACEUTICALS INC | 2013-07-10 | — | — | CN | disclosed |
| EP-2606031-A2 | AUTOTAXIN INHIBITORS AND USES THEREOF | Amira Pharmaceuticals, Inc. (US) | 2013-06-26 | — | — | EP | disclosed |
| US-20130150326-A1 | AUTOTAXIN INHIBITORS AND USES THEREOF | AMIRA PHARMACEUTICALS, INC. (US) | 2013-06-13 | — | — | US | disclosed |
| WO-2012024620-A2 | AUTOTAXIN INHIBITORS AND USES THEREOF | AMIRA PHARMACEUTICALS, INC. (US) | 2012-02-23 | — | — | WO | disclosed |
| US-8097733-B2 | Pyrazole derivatives as 5-LO-inhibitors | PFIZER INC. (US) | 2012-01-17 | — | — | US | disclosed |
| CN-101918392-A | Pyrazole derivatives as 5-LO inhibitors | PFIZER | 2010-12-15 | — | — | CN | disclosed |
| EP-2225229-A1 | PYRAZOLE DERIVATIVES AS 5-LO INHIBITORS | Pfizer Inc. (US) | 2010-09-08 | — | — | EP | disclosed |
| US-20090227634-A1 | Pyrazole Derivatives as 5-LO-Inhibitors | PFIZER INC. | 2009-09-10 | — | — | US | disclosed |
| WO-2009069044-A1 | PYRAZOLE DERIVATIVES AS 5-LO INHIBITORS | PFIZER INC. (US) | 2009-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150326-A1 | AUTOTAXIN INHIBITORS AND USES THEREOF | ENPP2, SERPINB1, SERPINE1 | ALDH1A1 4786/4885HPGD 3539/4885CYP1A1 4663/4885 |
| US-20250197420-A1 | MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | CFTR, ABCB1, PKD1 | ALDH1A1 3545/4885HPGD 1117/4885CYP1A1 1523/4885 |
| US-20090227634-A1 | Pyrazole Derivatives as 5-LO-Inhibitors | ALOX5, ALOX15, CYP3A5 | ALDH1A1 224/4885HPGD 58/4885CYP1A1 50/4885 |
| US-20250214977-A1 | STAT6 INHIBITORS AND USES THEREOF | STAT6, STAT5B, STAT5A | ALDH1A1 3523/4885HPGD 3777/4885CYP1A1 4562/4885 |
| US-20250205219-A1 | TARGETED DEGRADATION OF VAV1 | VAV1, KRAS, CBL | ALDH1A1 3624/4885HPGD 4537/4885CYP1A1 4376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.